JOP20190040A1 - توليفة من ناهضات fxr - Google Patents

توليفة من ناهضات fxr

Info

Publication number
JOP20190040A1
JOP20190040A1 JOP/2019/0040A JOP20190040A JOP20190040A1 JO P20190040 A1 JOP20190040 A1 JO P20190040A1 JO P20190040 A JOP20190040 A JO P20190040A JO P20190040 A1 JOP20190040 A1 JO P20190040A1
Authority
JO
Jordan
Prior art keywords
combination
fxr agonists
fxr
farnesoid
agonist
Prior art date
Application number
JOP/2019/0040A
Other languages
English (en)
Inventor
Andreas Bauer
Patrick Mueller
Bryan Laffitte
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of JOP20190040A1 publication Critical patent/JOP20190040A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

يتعلق الاختراع الحالي بتركيبات صيدلانية تتضمن ناهض مستقبل X فارنسيويد (FXR) وعامل علاجي آخر، على وجه الخصوص لعلاج أو الوقاية من أمراض أو اضطرابات الكبد. الشكل 1
JOP/2019/0040A 2016-09-14 2017-06-16 توليفة من ناهضات fxr JOP20190040A1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662394446P 2016-09-14 2016-09-14

Publications (1)

Publication Number Publication Date
JOP20190040A1 true JOP20190040A1 (ar) 2019-03-10

Family

ID=60043251

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2019/0040A JOP20190040A1 (ar) 2016-09-14 2017-06-16 توليفة من ناهضات fxr

Country Status (23)

Country Link
US (1) US20210290610A1 (ar)
EP (1) EP3512558A1 (ar)
JP (1) JP6878596B2 (ar)
KR (1) KR102218498B1 (ar)
CN (1) CN109689105A (ar)
AR (1) AR109652A1 (ar)
AU (2) AU2017328999B2 (ar)
BR (1) BR112019004684A2 (ar)
CA (1) CA3036760A1 (ar)
CL (1) CL2019000625A1 (ar)
CO (1) CO2019002245A2 (ar)
CR (1) CR20190125A (ar)
EC (1) ECSP19016844A (ar)
IL (1) IL264628A (ar)
JO (1) JOP20190040A1 (ar)
MX (1) MX2019003021A (ar)
PE (1) PE20190972A1 (ar)
PH (1) PH12019500326A1 (ar)
RU (1) RU2019110780A (ar)
SG (1) SG11201900651PA (ar)
TW (1) TW201811372A (ar)
WO (1) WO2018051230A1 (ar)
ZA (1) ZA201900528B (ar)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3585384A1 (en) * 2017-02-24 2020-01-01 Genfit Pharmaceutical compositions for combination therapy
CA3100635A1 (en) 2018-05-31 2019-12-05 Novartis Ag Combinations comprising tropifexor and cenicriviroc
CA3139750A1 (en) * 2019-07-18 2021-01-21 Jacky Vonderscher Improved treatment using eyp001
CN114929219A (zh) * 2019-12-20 2022-08-19 诺华股份有限公司 使用整联蛋白抑制剂组合治疗肝脏疾病
CN112402430A (zh) * 2020-12-11 2021-02-26 大连医科大学 泽泻醇b-23-醋酸酯在预防和治疗急性肾损伤中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6987121B2 (en) * 2002-04-25 2006-01-17 Smithkline Beecham Corporation Compositions and methods for hepatoprotection and treatment of cholestasis
PL2370442T3 (pl) * 2008-11-26 2013-08-30 Pfizer 3-Aminocyklopentanokarboksamidy jako modulatory receptora chemokiny
US8383812B2 (en) 2009-10-13 2013-02-26 Bristol-Myers Squibb Company N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-A][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline forms and processes
CU24152B1 (es) * 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
MY175903A (en) * 2013-11-05 2020-07-15 Novartis Ag Compositions and methods for modulating farnesoid x receptors
JP2017510572A (ja) * 2014-03-13 2017-04-13 ソーク インスティチュート フォー バイオロジカル スタディーズ Ｆｘｒアゴニストならびに作製および使用のための方法
JP2017526713A (ja) * 2014-09-12 2017-09-14 トビラ セラピューティクス， インコーポレイテッド 線維症を処置するためのセニクリビロック併用療法
CN107106555A (zh) * 2014-12-18 2017-08-29 诺华股份有限公司 氮杂双环辛烷衍生物作为fxr激动剂在治疗肝脏和胃肠疾病中的应用
KR20180115700A (ko) * 2016-02-22 2018-10-23 노파르티스 아게 Fxr 효능제를 사용하는 방법

Also Published As

Publication number Publication date
CL2019000625A1 (es) 2019-05-17
CR20190125A (es) 2019-06-04
US20210290610A1 (en) 2021-09-23
ECSP19016844A (es) 2019-03-29
AU2020201980A1 (en) 2020-04-09
KR102218498B1 (ko) 2021-02-22
AU2017328999B2 (en) 2019-12-19
EP3512558A1 (en) 2019-07-24
ZA201900528B (en) 2021-06-30
CA3036760A1 (en) 2018-03-22
IL264628A (en) 2019-02-28
PH12019500326A1 (en) 2019-11-11
MX2019003021A (es) 2019-09-26
RU2019110780A (ru) 2020-10-15
CN109689105A (zh) 2019-04-26
TW201811372A (zh) 2018-04-01
JP6878596B2 (ja) 2021-05-26
PE20190972A1 (es) 2019-07-09
AU2017328999A1 (en) 2019-02-21
KR20190044666A (ko) 2019-04-30
SG11201900651PA (en) 2019-04-29
WO2018051230A1 (en) 2018-03-22
RU2019110780A3 (ar) 2020-11-30
JP2019526644A (ja) 2019-09-19
CO2019002245A2 (es) 2019-05-31
AR109652A1 (es) 2019-01-09
BR112019004684A2 (pt) 2019-05-28

Similar Documents

Publication Publication Date Title
PH12019502058A1 (en) Farnesoid x receptor agonists and uses thereof
PH12019500326A1 (en) Combination of fxr agonists
PH12018500586A1 (en) Farnesoid x receptor agonists and uses thereof
PH12018501656A1 (en) Methods for using fxr agonists
IL283840A (en) Preparations for administering therapeutic substances and methods for their use and preparation
SG10201807625PA (en) Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
SA518400356B1 (ar) مثبطات الأرجيناز واستخداماتها العلاجية
MX2019003889A (es) Composiciones de combinacion que comprenden agonistas de fxr para tratar o prevenir una enfermedad o trastorno fibrotico o cirrotico.
PH12021550605A1 (en) Farnesoid x receptor agonists and uses thereof
SG10201808053XA (en) Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
PH12018502109A1 (en) Medicine obtained by combining fxr agonist and arb
MX2019014114A (es) Formulaciones para el tratamiento del trastorno de estres post-traumatico.
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
PH12017500436A1 (en) Novel pharmaceutical composition for prevention and/or treatment of urinary incontinence
MX2018013573A (es) Ciertos inhibidores de la proteína cinasa.
PH12019500327A1 (en) Indazole compounds for use in tendon and/or ligament injuries
MX2017010277A (es) Cenicriviroc para el tratamiento de la fibrosis.
MX2020005557A (es) Agonistas de fxr para el tratamiento de enfermedades hepaticas.
MX2019015280A (es) Composiciones de estatinas y metodos para su uso en el tratamiento de sinucleinopatias.
EA201990481A1 (ru) Тройная комбинация обратных агонистов рецептора гистамина-3, ингибиторов ацетилхолинэстеразы и антагониста рецептора nmda
EP3781194A4 (en) COMPOSITIONS AND METHODS FOR SELECTIVE DELIVERY OF THERAPEUTIC AND IMAGING AGENTS
EP3856892A4 (en) COMPOSITIONS AND METHODS FOR IN SITU DELIVERY OF THERAPEUTIC AND DIAGNOSTIC AGENTS
MX2018006157A (es) Dispositivos y composiciones de administracion transdermica resistentes al abuso que comprenden un agonista de opioide y un derivado de n-oxido administrado por la ruta no transdermica de un antagonista de opioide para el tratamiento del dolor.
UA101950U (uk) Фармацевтична композиція для лікування і профілактики застуди